Concepts (168)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Skin | 6 | 2020 | 2096 | 1.13 | Why? |
| Scleroderma, Localized | 3 | 2018 | 25 | 1.07 | Why? |
| Dermatitis, Exfoliative | 3 | 2020 | 50 | 0.95 | Why? |
| Nevus, Pigmented | 2 | 2018 | 54 | 0.90 | Why? |
| Psoriasis | 7 | 2020 | 1739 | 0.90 | Why? |
| Skin Neoplasms | 4 | 2018 | 1679 | 0.85 | Why? |
| Skin Care | 1 | 2020 | 49 | 0.82 | Why? |
| Mite Infestations | 1 | 2019 | 6 | 0.81 | Why? |
| Lip Neoplasms | 1 | 2019 | 8 | 0.79 | Why? |
| Blister | 2 | 2017 | 119 | 0.78 | Why? |
| Hydroquinones | 1 | 2018 | 8 | 0.78 | Why? |
| Tinea | 1 | 2019 | 22 | 0.78 | Why? |
| Skin Lightening Preparations | 1 | 2018 | 7 | 0.78 | Why? |
| Keratolytic Agents | 1 | 2018 | 16 | 0.77 | Why? |
| Acitretin | 1 | 2018 | 23 | 0.77 | Why? |
| Lichen Planus, Oral | 1 | 2019 | 27 | 0.76 | Why? |
| Molluscum Contagiosum | 1 | 2018 | 11 | 0.75 | Why? |
| Gloves, Protective | 1 | 2020 | 249 | 0.74 | Why? |
| Hypopigmentation | 1 | 2018 | 28 | 0.74 | Why? |
| Prurigo | 1 | 2018 | 17 | 0.74 | Why? |
| Pityriasis Rubra Pilaris | 1 | 2018 | 26 | 0.73 | Why? |
| Porphyria Cutanea Tarda | 1 | 2017 | 8 | 0.73 | Why? |
| Erythema | 2 | 2020 | 400 | 0.71 | Why? |
| Photosensitivity Disorders | 1 | 2017 | 14 | 0.71 | Why? |
| Sweet Syndrome | 1 | 2018 | 54 | 0.71 | Why? |
| Paraneoplastic Syndromes | 1 | 2017 | 28 | 0.70 | Why? |
| Hyperpigmentation | 1 | 2018 | 42 | 0.70 | Why? |
| Skin Pigmentation | 1 | 2018 | 98 | 0.69 | Why? |
| Epidermolysis Bullosa | 1 | 2017 | 60 | 0.67 | Why? |
| Skin Aging | 1 | 2017 | 55 | 0.67 | Why? |
| Scalp Dermatoses | 1 | 2017 | 59 | 0.66 | Why? |
| Periodontal Diseases | 1 | 2017 | 87 | 0.62 | Why? |
| Pruritus | 1 | 2018 | 215 | 0.62 | Why? |
| Face | 1 | 2019 | 301 | 0.60 | Why? |
| Dermatitis, Occupational | 1 | 2020 | 310 | 0.59 | Why? |
| Etanercept | 1 | 2016 | 162 | 0.59 | Why? |
| Scleroderma, Systemic | 2 | 2018 | 583 | 0.54 | Why? |
| Prednisone | 1 | 2018 | 652 | 0.53 | Why? |
| Graft vs Host Disease | 1 | 2017 | 501 | 0.51 | Why? |
| Syphilis | 1 | 2017 | 318 | 0.50 | Why? |
| Alopecia | 1 | 2017 | 351 | 0.48 | Why? |
| Occupational Exposure | 2 | 2020 | 4742 | 0.45 | Why? |
| Skin Diseases | 4 | 2020 | 2509 | 0.43 | Why? |
| Carcinoma, Squamous Cell | 1 | 2019 | 902 | 0.40 | Why? |
| Thalidomide | 2 | 2020 | 247 | 0.34 | Why? |
| Pregnancy Complications | 1 | 2018 | 1388 | 0.32 | Why? |
| Glucocorticoids | 2 | 2018 | 4431 | 0.29 | Why? |
| Melanoma | 1 | 2016 | 1229 | 0.29 | Why? |
| Diabetes Complications | 1 | 2017 | 2358 | 0.29 | Why? |
| Occupational Diseases | 1 | 2020 | 2787 | 0.28 | Why? |
| Dermatology | 1 | 2020 | 1999 | 0.28 | Why? |
| Hidradenitis Suppurativa | 2 | 2020 | 309 | 0.27 | Why? |
| Arthritis, Psoriatic | 2 | 2021 | 625 | 0.25 | Why? |
| Biopsy | 4 | 2020 | 2811 | 0.24 | Why? |
| Scleredema Adultorum | 1 | 2020 | 6 | 0.22 | Why? |
| Lichen Sclerosus et Atrophicus | 1 | 2020 | 6 | 0.22 | Why? |
| De Lange Syndrome | 1 | 2020 | 18 | 0.21 | Why? |
| Skin Diseases, Genetic | 1 | 2020 | 65 | 0.21 | Why? |
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2020 | 1454 | 0.20 | Why? |
| Disease Progression | 1 | 2019 | 13580 | 0.20 | Why? |
| Mites | 1 | 2019 | 26 | 0.20 | Why? |
| Melanosis | 1 | 2019 | 29 | 0.19 | Why? |
| Anti-Bacterial Agents | 2 | 2017 | 10083 | 0.18 | Why? |
| Fusidic Acid | 1 | 2017 | 21 | 0.18 | Why? |
| Clobetasol | 1 | 2017 | 25 | 0.18 | Why? |
| Ossification, Heterotopic | 1 | 2018 | 60 | 0.18 | Why? |
| Erythema Multiforme | 1 | 2020 | 172 | 0.18 | Why? |
| Doxycycline | 1 | 2020 | 307 | 0.18 | Why? |
| Immunosuppressive Agents | 1 | 2016 | 6331 | 0.18 | Why? |
| Necrosis | 1 | 2020 | 532 | 0.17 | Why? |
| Cell Transformation, Neoplastic | 1 | 2019 | 191 | 0.17 | Why? |
| Pigmentation Disorders | 1 | 2017 | 29 | 0.17 | Why? |
| Cicatrix | 1 | 2019 | 129 | 0.17 | Why? |
| Remission Induction | 2 | 2018 | 950 | 0.17 | Why? |
| Purpura | 1 | 2020 | 310 | 0.17 | Why? |
| Self-Assessment | 1 | 2018 | 165 | 0.17 | Why? |
| Raynaud Disease | 1 | 2017 | 86 | 0.16 | Why? |
| Disease Transmission, Infectious | 1 | 2020 | 9044 | 0.16 | Why? |
| Adalimumab | 1 | 2020 | 389 | 0.16 | Why? |
| Neoplasm Invasiveness | 1 | 2019 | 582 | 0.16 | Why? |
| Hand Dermatoses | 1 | 2020 | 284 | 0.15 | Why? |
| Ustekinumab | 1 | 2017 | 216 | 0.15 | Why? |
| Rifampin | 1 | 2017 | 276 | 0.15 | Why? |
| Personal Protective Equipment | 1 | 2020 | 15978 | 0.15 | Why? |
| Urticaria | 1 | 2020 | 472 | 0.14 | Why? |
| Uveitis | 1 | 2017 | 233 | 0.14 | Why? |
| Dermatologic Agents | 2 | 2017 | 489 | 0.14 | Why? |
| Dermoscopy | 1 | 2018 | 346 | 0.13 | Why? |
| Humans | 32 | 2021 | 930598 | 0.13 | Why? |
| Methotrexate | 1 | 2017 | 471 | 0.12 | Why? |
| Male | 18 | 2020 | 367725 | 0.12 | Why? |
| Ageusia | 1 | 2020 | 918 | 0.12 | Why? |
| Polyethylene Glycols | 1 | 2017 | 574 | 0.12 | Why? |
| Bronchoconstriction | 1 | 1992 | 16 | 0.12 | Why? |
| Sulfur Dioxide | 1 | 1992 | 99 | 0.12 | Why? |
| Interferon-beta | 1 | 2017 | 979 | 0.11 | Why? |
| Multiple Sclerosis, Relapsing-Remitting | 1 | 2017 | 529 | 0.11 | Why? |
| Infection Control | 1 | 2020 | 23131 | 0.11 | Why? |
| Exanthema | 1 | 2020 | 1097 | 0.11 | Why? |
| Methicillin-Resistant Staphylococcus aureus | 1 | 2017 | 711 | 0.11 | Why? |
| Treatment Outcome | 6 | 2020 | 51732 | 0.11 | Why? |
| Disinfectants | 1 | 2020 | 1077 | 0.10 | Why? |
| Antibodies, Monoclonal, Humanized | 3 | 2021 | 9335 | 0.10 | Why? |
| Diagnosis, Differential | 4 | 2018 | 7220 | 0.10 | Why? |
| Chilblains | 1 | 2020 | 1156 | 0.10 | Why? |
| Reconstructive Surgical Procedures | 1 | 2019 | 860 | 0.09 | Why? |
| Microbial Sensitivity Tests | 1 | 2017 | 2886 | 0.09 | Why? |
| Betacoronavirus | 4 | 2020 | 204454 | 0.09 | Why? |
| Italy | 4 | 2020 | 38444 | 0.08 | Why? |
| Aged | 11 | 2020 | 215776 | 0.08 | Why? |
| Autoantibodies | 1 | 2017 | 2094 | 0.08 | Why? |
| Pneumonia, Viral | 5 | 2020 | 243684 | 0.08 | Why? |
| Coronavirus Infections | 5 | 2020 | 253789 | 0.08 | Why? |
| Lip Diseases | 1 | 2004 | 11 | 0.07 | Why? |
| Leishmaniasis, Visceral | 1 | 2004 | 85 | 0.07 | Why? |
| Drug Therapy, Combination | 1 | 2017 | 7268 | 0.06 | Why? |
| Follow-Up Studies | 2 | 2020 | 17020 | 0.06 | Why? |
| Middle Aged | 11 | 2020 | 270681 | 0.06 | Why? |
| Phenobarbital | 1 | 1980 | 22 | 0.06 | Why? |
| Glutathione Transferase | 1 | 1980 | 86 | 0.05 | Why? |
| Immunologic Factors | 1 | 2017 | 4206 | 0.05 | Why? |
| Female | 14 | 2020 | 380317 | 0.05 | Why? |
| Systemic Inflammatory Response Syndrome | 1 | 2020 | 6653 | 0.05 | Why? |
| Down Syndrome | 1 | 2004 | 397 | 0.05 | Why? |
| Metaplasia | 1 | 2018 | 43 | 0.05 | Why? |
| Glutathione | 1 | 1980 | 280 | 0.05 | Why? |
| Sickness Impact Profile | 1 | 2018 | 56 | 0.05 | Why? |
| Adult | 8 | 2020 | 244371 | 0.05 | Why? |
| Antibodies, Monoclonal | 1 | 2017 | 8041 | 0.04 | Why? |
| Quality of Life | 1 | 2018 | 9820 | 0.04 | Why? |
| Critical Care | 1 | 2020 | 14081 | 0.04 | Why? |
| Pregnancy | 1 | 2018 | 23879 | 0.04 | Why? |
| Skin Diseases, Vesiculobullous | 1 | 2017 | 112 | 0.04 | Why? |
| Confidence Intervals | 1 | 2018 | 744 | 0.04 | Why? |
| Reference Values | 1 | 2018 | 795 | 0.04 | Why? |
| Injections, Subcutaneous | 1 | 2017 | 647 | 0.04 | Why? |
| Hydroxychloroquine | 1 | 2019 | 12447 | 0.04 | Why? |
| Statistics, Nonparametric | 1 | 2018 | 1008 | 0.04 | Why? |
| Air Pollutants | 1 | 1992 | 3110 | 0.03 | Why? |
| Abdomen | 1 | 2017 | 424 | 0.03 | Why? |
| Aged, 80 and over | 3 | 2020 | 88759 | 0.03 | Why? |
| Animals | 4 | 2019 | 78931 | 0.03 | Why? |
| Rare Diseases | 1 | 2017 | 373 | 0.03 | Why? |
| Sulfites | 1 | 1992 | 9 | 0.03 | Why? |
| Albuterol | 1 | 1992 | 105 | 0.03 | Why? |
| Young Adult | 2 | 2019 | 93724 | 0.03 | Why? |
| Guinea Pigs | 1 | 1992 | 420 | 0.03 | Why? |
| Surveys and Questionnaires | 1 | 2018 | 43792 | 0.03 | Why? |
| Medication Adherence | 1 | 2020 | 1270 | 0.03 | Why? |
| Pandemics | 5 | 2020 | 389249 | 0.03 | Why? |
| Child | 1 | 2018 | 70012 | 0.02 | Why? |
| Liver | 1 | 1980 | 4007 | 0.02 | Why? |
| Risk Assessment | 2 | 2020 | 25439 | 0.02 | Why? |
| Leishmania infantum | 1 | 2004 | 29 | 0.02 | Why? |
| Meglumine | 1 | 2004 | 26 | 0.02 | Why? |
| Antiprotozoal Agents | 1 | 2004 | 83 | 0.02 | Why? |
| Lung | 1 | 1992 | 31049 | 0.02 | Why? |
| Organometallic Compounds | 1 | 2004 | 206 | 0.01 | Why? |
| Drug Repositioning | 1 | 2020 | 5683 | 0.01 | Why? |
| Injections, Intramuscular | 1 | 2004 | 800 | 0.01 | Why? |
| Sex Factors | 1 | 2018 | 11014 | 0.01 | Why? |
| Severity of Illness Index | 2 | 2018 | 48226 | 0.01 | Why? |
| Case-Control Studies | 1 | 2018 | 17671 | 0.01 | Why? |
| Sensitivity and Specificity | 1 | 2018 | 22971 | 0.01 | Why? |
| Age Factors | 1 | 2018 | 21039 | 0.01 | Why? |
| Cytokines | 1 | 2018 | 15010 | 0.01 | Why? |
| Rats | 1 | 1980 | 2764 | 0.01 | Why? |
| Retrospective Studies | 1 | 2017 | 105322 | 0.00 | Why? |
Atzori's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(168)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(64)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_